Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balcinrenone + dapagliflozin versus dapagliflozin in heart failure with impaired kidney function
NL-OMON60961Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of balcinrenone and dapagliflozin in heart failure (HF) and chronic kidney disease (CKD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Time to first occurrence of composite cardiovascular death or heart failure event. Started Aug 2024; status: active, not recruiting.
02
Drugs
balcinrenonedapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON60961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60961.